17 Nov 2026, 16:14
Substantial Holders—
Announcement history available from 1 August 2025
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 17 Nov 2026, 16:14 | Change in substantial holding - Updated | Substantial Holders | — | 02002 | |
| 17 Nov 2026, 08:27 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 6 Nov 2026, 12:17 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 6 Nov 2026, 12:15 | Chair address - amendment | Letters & Addresses | — | 15002 | |
| 6 Nov 2026, 09:59 | Managing Director Address | Presentations | MS | 03026, 15001 | |
| 6 Nov 2026, 09:55 | Chair address | Letters & Addresses | — | 15002 | |
| 30 Oct 2026, 08:30 | CLINUVEL files NEURACTHEL Instant dossier | Company Update | MS | 11001 | |
| 15 Oct 2026, 08:18 | Notification of cessation of securities - CUV | Securities Administration | — | 06027 | |
| 6 Oct 2026, 08:54 | Section 708A Cleansing Statement | Securities Administration | — | 06018 | |
| 6 Oct 2026, 08:53 | Notification of cessation of securities - CUV | Securities Administration | — | 06027 | |
| 6 Oct 2026, 08:51 | Application for quotation of securities - CUV | Securities Administration | — | 06020 | |
| 6 Oct 2026, 08:17 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 2 Oct 2026, 18:56 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 2 Oct 2026, 08:57 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 | |
| 1 Oct 2026, 11:18 | New CUV105 vitiligo cases presented to EADV | Company Update | — | 11001 | |
| 24 Sept 2026, 08:19 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 18 Sept 2026, 17:12 | CLINUVEL date of Annual General Meeting | Meetings & Governance | — | 08006 | |
| 8 Sept 2026, 09:32 | CLINUVEL develops proprietary ZEROKIN device | Company Update | — | 11001 | |
| 2 Sept 2026, 08:15 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 27 Aug 2026, 12:33 | CLINUVEL considers Nasdaq listing, ASX delisting | Company Administration | MS | 12008 | |
| 27 Aug 2026, 12:28 | Investor Presentation | Financial Results | MS | 03003, 03026 | |
| 27 Aug 2026, 12:26 | Appendix 4G | Company Administration | — | 03025 | |
| 27 Aug 2026, 12:25 | Corporate Governance Statement | Company Administration | — | 03024 | |
| 27 Aug 2026, 12:24 | Dividend/Distribution - CUV | Dividends & Distributions | — | 10001, 10002, 10003 | |
| 27 Aug 2026, 12:22 | A decade of profitability provides U.S. expansion foundation | Financial Results | MS | 03003 | |
| 27 Aug 2026, 12:21 | Appendix 4E and Annual Report to Shareholders 2026 | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020, 10001, 10003 | |
| 20 Aug 2026, 09:07 | CLINUVEL Annual Results - Investor Webinar | Presentations | — | 03027, 14014 | |
| 14 Aug 2026, 08:16 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 12 Aug 2026, 09:12 | CLINUVEL's injectable peptide platform | Company Update | — | 11001 | |
| 30 July 2026, 08:57 | Commercial update on vitiligo | Company Update | MS | 11001 | |
| 28 July 2026, 08:56 | Update - SCENESSE in vitiligo | Company Update | MS | 11001 | |
| 27 July 2026, 08:48 | Notification of cessation of securities - CUV | Securities Administration | — | 06027 | |
| 23 July 2026, 09:11 | CLINUVEL strategic reorganisation to refocus on U.S. markets | Company Update | MS | 11001, 12008 | |
| 21 July 2026, 08:35 | CLINUVEL's ADS commences trading on Nasdaq | Securities Administration | — | 14011 | |
| 20 July 2026, 08:33 | CLINUVEL's ADS to commence trading on Nasdaq | Company Administration | — | 12008, 14011 | |
| 13 July 2026, 08:34 | SCENESSE approved for EPP in Canada | Company Update | MS | 11001 | |
| 2 July 2026, 11:36 | CLINUVEL confirms terms of CEO's Employment Agreement | Company Administration | — | 12008 | |
| 16 June 2026, 09:06 | CLINUVEL publicly files 20-F to U.S. SEC | Company Administration | MS | 12008 | |
| 2 June 2026, 09:26 | CLINUVEL US Non-Deal Roadshow Presentation | Presentations | — | 03026 | |
| 7 May 2026, 11:45 | Notification regarding unquoted securities - CUV | Securities Administration | — | 06021 | |
| 28 Apr 2026, 08:50 | CLINUVEL update on Level II ADR upgrade, Nasdaq uplist | Company Administration | MS | 12008 | |
| 27 Apr 2026, 08:42 | FDA relaxes SCENESSE postmarketing requirement | Company Update | MS | 11001 | |
| 24 Apr 2026, 08:56 | Final EMA scientific advice for pivotal Phase III vitiligo | Company Update | MS | 11001 | |
| 17 Apr 2026, 09:04 | Notification of cessation of securities - CUV | Securities Administration | — | 06027 | |
| 13 Apr 2026, 08:50 | Section 708A Cleansing Statement | Securities Administration | — | 06018 | |
| 13 Apr 2026, 08:49 | Application for quotation of securities - CUV | Securities Administration | — | 06020 | |
| 13 Apr 2026, 08:18 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 2 Apr 2026, 12:15 | CLINUVEL reports highlights from AAD 2026 | Company Update | — | 11001 | |
| 27 Mar 2026, 08:35 | CLINUVEL's global programs showcased at AAD | Company Update | MS | 11001 | |
| 20 Mar 2026, 08:30 | Chair Letter to Shareholders | Letters & Addresses | MS | 16002 |